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Abstract— A series of pro-nucleotide phosphoramidates and phosphorodiamidates of the antiviral lead compound 3’-deoxy-3’-
fluorothymidine (FLT) have been designed and synthesized. In vitro antiretroviral and cytostatic studies revealed potent (sub-micromolar) 
inhibition of HIV-1 and HIV-2 replication, with retention of activity in thymidine kinase-negative cell models, as predicted by the Pro-
Tide concept. 
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Despite their crucial and widespread role as approved 
therapeutics for antiviral
1
 and anticancer
2
 therapy, the 
activity of nucleoside analogues is compromised by 
their requirement for active transporter-mediated cell 
uptake and bioactivation, usually via three successive 
phosphorylation steps. Since initial nucleoside kinase-
catalysed phosphorylation is frequently the rate-limiting 
step in nucleoside drug activation, a number of pro-drug 
(pro-nucleotide) monophosphate strategies have been 
developed to circumvent delivery, uptake and metabolic 
activation issues. 
 
One of the most widely used pro-nucleotide strategies is 
the approach pioneered by McGuigan,
3,4
 in which the 
monophosphate is masked as a phosphoramidate,
5
 or in 
more recent modalities as a phosphorodiamidate.
6
 
Following passive diffusion through the cell membrane, 
the pro-nucleotide (ProTide) breaks down within the 
cell via a well-studied mechanism to release the 
nucleoside monophosphate, trapped intracellularly and 
primed for further phosphorylation. The ProTide 
approach has been applied to improve efficacy for a 
wide range of antiviral and anticancer nucleosides. 
Recent highlights include the clinical trial candidates 
INX-189 (hepatitis C virus, to Phase 2)
7
 and a pro-
nucleotide of the cancer chemotherapeutic gemcitabine  
(NUC-1031, Phase 1, ongoing),
8
 shown in Figure 1. 
 
Figure 1.  Chemical structures of ProTides INX-189 and NUC-
1031. 
Fluorine is well known to impart rather special 
physicochemical and pharmacological properties on 
drug candidates, and is present in 15-20% of currently 
approved drugs overall.
9
 Several fluorinated nucleosides 
have been applied as both therapeutic agents and in 
diagnostic imaging. Examples of fluorinated nucleoside 
antivirals include emtricitabine (HIV),
10
 clevudine 
(HBV)
11
 and trifluridine (HSV; cancer).
12,13
 Besides 
trifuridine, fluorinated nucleoside-based anticancer 
drugs include also the 5-fluorouracil pro-drug such as 
capecitabine
14
 and gemcitabine;
15
 and the related purine 
nucleosides fludarabine and clofarabine.
16
 
 
3’-Deoxy-3’-fluorothymidine (FLT) is a particularly 
interesting fluorinated nucleoside derivative possessing 
a variety of biological properties. The major clinical 
application of FLT is in the non-invasive diagnostic 
imaging of tumour proliferation using Positron 
Emission Tomography (PET), where the 
18
F 
radiolabelled analogue (
18
FLT, t1/2 = 110 min.) is 
  2 
routinely employed as a highly sensitive imaging 
probe.
17
 In terms of therapeutic application, FLT (also 
known as alovudine) has been shown to be a more 
potent inhibitor of HIV replication than the well-known 
anti-retroviral agent AZT. In vitro studies have shown 
that FLT inhibits replication of nucleoside analogue 
reverse transcriptase inhibitor (NRTI)-resistant HIV 
strains.
18
 Further clinical development of FLT was 
halted, however, due to toxicological safety concerns.
19
 
Previous preliminary work on FLT pro-nucleotides as 
HIV inhibitors suggested the possibility to retain the 
potent activity of the parent compound using a ProTide-
based strategy.
20
 In this paper, we describe the synthesis 
and in vitro evaluation of both phosphoramidate (3a-m) 
and phosphorodiamidate (5a-b) pro-nucleotide 
derivatives of FLT as antiretroviral and anticancer 
agents. These studies test the hypothesis that application 
of the ProTide delivery concept might generate highly 
potent new nucleotide analogues that are able to by-pass 
the requirement for a functional thymidine kinase (TK). 
Synthesis of the FLT phosphoramidates was 
accomplished through application of known pro-
nucleotide chemistry.
5
 Reaction of the commercially 
available FLT (1, Carbosynth U.K.) with a range of 
previously reported aryloxyphosphorochloridates (2a-
m), promoted by tert-butylmagnesium chloride as a 
hindered base in THF, provided the target 
phosphoramidate products in low to moderate isolated 
yield (high yield based on recovered starting material, 
BORSM) following column chromatography (Scheme 
1).
21,22
 
 
We then tried to synthesize diamidate prodrugs of FLT 
according to the trimethyl phosphate method used 
previously in our laboratory.
23
 Unfortunately, after 5h of 
reaction at -78 
o
C in the presence of TMP and POCl3, 
the signal of the desired intermediate 4 on 
31
P NMR was 
barely visible. After a further 15h in the presence of L-
Ala neopentyl ester and DIPEA, no signal of the desired 
diamidate prodrug was observed on 
31
P NMR. We can 
explain this by a lack of solubility of FLT in the organic 
solvents used. Eventually symmetrical FLT 
phosphorodiamidates (5a-b) were synthesized 
according to literature methods
6,24
 by treating FLT with 
phosphoryl chloride under basic conditions to generate 
an intermediate dichloridate (4) which was not isolated. 
Reaction of FLT dichloridate with further triethylamine, 
followed by excess -amino acid ester, gave the 
required FLT phosphorodiamidates after purification by 
column chromatography and preparative TLC (Scheme 
1).
25,26
  
 
Scheme 1. Synthesis of FLT pro-nucleotides
a,b 
 
The resulting FLT Pro-Tides were evaluated for their in 
vitro inhibitory effect on the replication of HIV-1 and 
HIV-2 in human T-lymphocyte (CEM) cell cultures, 
according to previously described methods.
24,27
 
Importantly, TK
-
 mutant CEM cells were included to 
examine the hypothesis that the ProTide derivatives, 
unlike the parent compound FLT, would be able to by-
pass the requirement for TK-directed phosphorylation 
and would be active in this test. The results of the HIV 
assays are shown in Table 1. FLT (1) was used as a 
positive control, confirming potent anti-HIV-1 and -
HIV-2 activity in the TK-expressing CEM cells (EC50 = 
6.2 and 18 nM, respectively), but not in the TK 
knockout CEM mutant cells (EC50 >50 M). The >1000 
fold loss of activity of (1) in the TK
-
 assay is notable. 
Cpd. EC50 / M (CEM/0) EC50 / M 
(CEM/TK
-
) 
HIV-1  HIV-2 HIV-2 
3a 0.55 ± 0.21 1.3 ± 0.14 4.7 ± 4.8 
3b 0.10 ± 0.068 0.24 ± 0.23 1.3 ± 0.71 
3c 0.75 ± 0.0 1.1 ± 0.23 28 ± 2.1 
3d 0.29 ± 0.16 0.90 ± 0.71 >50 
3e 0.13 ± 0.11 0.18 ± 0.049 2.0 ± 0.0 
3f 0.43 ± 0.35 0.65 ± 0.35 3.0 ± 1.3 
3g 0.16 ± 0.028 0.18 ± 0.071 5.2 ± 0.92 
3h 0.56 ± 0.23 1.0 ± 0.27 >50 
3i 2.3 ± 1.4 4.7 ± 2.4 >50 
3j 0.048 ± 0.078 0.14 ± 0.0071 2.0 ± 1.1 
3k 0.032 ± 0.0057 0.080 ± 0.0 0.87 ± 0.33 
3l 0.12 ± 0.014 0.18 ± 0.078 2.1 ± 1.2 
3m 0.65 ± 0.21 1.6 ± 0.38 89 ± 8.5 
5a 0.036 ± 0.0042 0.13 ± 0.0071 1.0 ± 0.87 
5b 0.017 ± 0.0092 0.045 ± 0.012 20 ± 0.71 
1 0.0062 ± 0.0021 0.018 ± 0.014 >50 
Table 1.  Anti-HIV-1 and –HIV-2 activity (EC50, M) values in 
human T-lymphocyte (CEM) cell cultures. Results are expressed 
as mean values of at least 2 to 3 independent experiments. 
 
Examination of the in vitro antiretroviral activity 
indicates some interesting and novel findings. Although 
the new pro-nucleotides were not generally found to be 
as active as FLT in TK-positive cells (CEM/0), some 
phosphoramidates (e.g. 3j-k) and phosphorodiamidates 
(e.g. 5a-b) gave EC50 values in the middle (≤100 nM) 
nanomolar concentration range for HIV-1 and/or HIV-2. 
Phosphorodiamidate (5b) (R = neopentyl) was found to 
be the most potent compound in the assays. Importantly, 
the test compounds were able to retain moderate activity 
in the CEM/TK
-
 (TK mutant) cell cultures in the lower 
micromolar range, unlike FLT (with the exception of 
ProTides 3d, 3h-i, 3m and 5b). Based on the overall 
profile across these three test assays, FLT 
phosphoramidate (3k, R = naphthyl; R’ = neopentyl) 
and FLT phosphorodiamidate (5a, R = Bn) are the most 
potent and promising compounds for further study. 
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Importantly, compound (3k) shows only a 10-fold loss 
of activity in the TK knockout CEM mutant cell assay, 
versus >1000-fold for compound (1). 
 
In vitro examination of the cytostatic potential of the 
FLT ProTides was studied in the human T-lymphocyte 
CEM cells (both wild-type TK and TK-deficient (TK
-
)), 
and the murine leukaemia cell line L1210, according to 
previously reported protocols.
24,28
 The results of these 
studies are shown in Table 2. 
 
Cpd. IC50 / M  
CEM/0  CEM/TK
-
 L1210 
3a >250 >250 8.2 ± 3.7 
3b >250 >250 4.4 ± 1.4 
3c 145 ± 38 >250 23 ± 1 
3d 124 ± 58 >250 6.3 ± 0.6 
3e 117 ± 88 172 ± 59 5.8 ± 0.6 
3f 66 ± 10 112 ± 52 3.0 ± 1.2 
3g 81 ± 1 138 ± 5 6.0 ± 0.9 
3h 206 ± 62 >250 24 ± 2 
3i 148 ± 17 >250 36 ± 3 
3j 13 ± 2 20 ± 3 2.9 ± 1.2 
3k 14 ± 1 20 ± 3 1.9 ± 1.1 
3l 54 ± 5 57 ± 8 5.2 ± 3.3 
3m 100 ± 12 >250 43 ± 13 
5a 17 ± 6 22 ± 5 1.2 ± 1.1 
5b 66 ± 11 43 ± 34 3.8 ± 2.7 
1 39 ± 26 >250 0.081 ± 0.037 
Table 2.  Cytostatic activity (IC50, M) values in human T-
lymphocyte (CEM) and murine leukaemia (L1210) cells. Results 
are expressed as mean values of at least 2 to 3 independent 
experiments. 
 
Examination of Table 2 reveals few compounds with 
significantly potent cytostatic activity within these cell 
line models. The most potent activity was observed in 
the L1210/0 leukaemia cell line, where low micromolar 
IC50 values was found for a variety of compounds, but 
where cytostatic activity was lower than for the parental 
FLT (1). Gratifyingly, compounds with moderate 
activity in the CEM/0 cell line (such as 3j, 3k and 5a) 
were largely able to retain activity within the CEM/TK
-
 
tumour cell model (unlike the parent FLT) and were 
non-toxic at antiviral concentrations. 
 
In conclusion, the preparation of a series of 
phosphoramidate and phosphorodiamidate Pro-Tides of 
the antiviral lead compound FLT have been prepared. In 
vitro screening with anti-HIV and anticancer model 
systems revealed compounds with generally lower 
activity than the parent lead, but with the ability to 
retain activity within TK
-
 models. This retention of 
activity across the test panels provides further evidence 
for the potential of ProTides to, at least in part, by-pass 
the need of thymidine kinase-catalysed phosphorylation 
and deliver the intact nucleoside monophosphate ready 
for further metabolic conversion to the biologically 
active form. 
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27. Anti-HIV Activity Assays: Inhibition of HIV-1(IIIB)- and 
HIV-2(ROD)-induced cytopathicity in CEM cell cultures was 
measured in microtiter 96-well plates containing ~ 3 x 105 
CEM cells/mL infected with 100 CCID50 of HIV per 
milliliter and containing appropriate dilutions of the test 
compounds. After 4-5 days of incubation at 37 ºC in a CO2-
controlled humidified atmosphere, CEM giant (syncytium) 
cell formation was examined microscopically. The EC50 
(50% effective concentration) was defined as the compound 
concentration required to inhibit HIV-induced giant cell 
formation by 50%. 
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28. Cytostatic Activity Assays: All assays were performed in 96-
well microtiter plates. To each well were added (5-7.5) x 104 
tumour cells and a given amount of the test compound. The 
cells were allowed to proliferate for 48 h (murine 
lymphocytic CEM and human leukaemia L1210 cells) at 37 
°C in a humidified CO2-controlled atmosphere. At the end of 
the incubation period, the cells were counted in a Coulter 
counter. The IC50 (50% inhibitory concentration) was defined 
as the concentration of the compound that inhibited cell 
proliferation by 50%. 
 
 
 
 
  6 
INX-189 NUC-1031
O
OH
N
O
N
N
N
NH2
O
OH
Me
P
O
O NH
O
O
O
OH
N
N
NH2
O
O
F
F
P
O
O
NH
O
O
 
 
Figure 1. Chemical structures of ProTides INX-189 and NUC-1031. 
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Scheme 1. Synthesis of FLT pro-nucleotides. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
